Illuminating (HTLV-1)-induced adult T-cell leukemia/lymphoma transcriptomic signature: A systems virology approach.
Adult T-cell lymphoma/leukemia
Bioinformatics
HTLV-1
Network analysis
RT-qPCR
WGCNA
Journal
Virus research
ISSN: 1872-7492
Titre abrégé: Virus Res
Pays: Netherlands
ID NLM: 8410979
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
19
07
2023
revised:
01
10
2023
accepted:
04
10
2023
medline:
3
11
2023
pubmed:
14
10
2023
entrez:
13
10
2023
Statut:
ppublish
Résumé
Adult T-cell leukemia/lymphoma (ATLL) is a poor prognosis malignancy of peripheral T-cells caused by human T-cell leukemia virus type 1 (HTLV-1). The low survival rates observed in the patients are the result of the lack of sufficient knowledge about the disease pathogenesis. In the present study, we first identified differentially expressed genes in ATLL patients and the cellular signaling pathways affected by them. Then, genes of these pathways were subjected to more comprehensive evaluations, including WGCNA and module validation studies on five external datasets. Finally, potential biomarkers were selected for qRT-PCR validation. Thirteen signaling pathways, including Apoptosis, Human T-cell leukemia virus 1 infection, IL-17 signaling pathway, pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, and seven others were selected for deeper investigations. Results of our in-depth bioinformatics evaluations, highlighted pathways related to regulation of immune responses, T-cell receptor and activation, regulation of cell signaling receptors and messengers, Wnt signaling pathway, and apoptosis as key players in ATLL pathogenesis. MAPK3, PIK3CD, KRAS, NFKB1, TNF, PLCB3, PLCB2, PLCB1, MAPK11, JUN, ITPR1, ADCY1, GNAQ, ADCY3, ADCY4, CHEK1, CCND1, SOS2, BAX, FOS and GNA12 were identified as possible biomarkers. Upregulation of ADCY1 and ADCY3 genes was confirmed via qRT-PCR. In this study, we performed a deep bioinformatic examination on a limited set of genes with high probabilities of involvement in the pathogenesis of ATLL. Our results highlighted signaling pathways and genes with potential key roles in disease formation and resistance against current treatment strategies. Further studies are required to test the possible benefits of highlighted genes as biomarkers and targets of treatment.
Sections du résumé
BACKGROUND
Adult T-cell leukemia/lymphoma (ATLL) is a poor prognosis malignancy of peripheral T-cells caused by human T-cell leukemia virus type 1 (HTLV-1). The low survival rates observed in the patients are the result of the lack of sufficient knowledge about the disease pathogenesis.
METHODS
In the present study, we first identified differentially expressed genes in ATLL patients and the cellular signaling pathways affected by them. Then, genes of these pathways were subjected to more comprehensive evaluations, including WGCNA and module validation studies on five external datasets. Finally, potential biomarkers were selected for qRT-PCR validation.
RESULTS
Thirteen signaling pathways, including Apoptosis, Human T-cell leukemia virus 1 infection, IL-17 signaling pathway, pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, and seven others were selected for deeper investigations. Results of our in-depth bioinformatics evaluations, highlighted pathways related to regulation of immune responses, T-cell receptor and activation, regulation of cell signaling receptors and messengers, Wnt signaling pathway, and apoptosis as key players in ATLL pathogenesis. MAPK3, PIK3CD, KRAS, NFKB1, TNF, PLCB3, PLCB2, PLCB1, MAPK11, JUN, ITPR1, ADCY1, GNAQ, ADCY3, ADCY4, CHEK1, CCND1, SOS2, BAX, FOS and GNA12 were identified as possible biomarkers. Upregulation of ADCY1 and ADCY3 genes was confirmed via qRT-PCR.
CONCLUSIONS
In this study, we performed a deep bioinformatic examination on a limited set of genes with high probabilities of involvement in the pathogenesis of ATLL. Our results highlighted signaling pathways and genes with potential key roles in disease formation and resistance against current treatment strategies. Further studies are required to test the possible benefits of highlighted genes as biomarkers and targets of treatment.
Identifiants
pubmed: 37832654
pii: S0168-1702(23)00199-5
doi: 10.1016/j.virusres.2023.199237
pmc: PMC10618755
pii:
doi:
Substances chimiques
Receptors, Cell Surface
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
199237Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nat Rev Mol Cell Biol. 2003 Sep;4(9):733-8
pubmed: 14506476
Front Oncol. 2022 Jun 27;12:829212
pubmed: 35832555
Sci Rep. 2021 Feb 18;11(1):4114
pubmed: 33603066
J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):79-110
pubmed: 12503609
Cell Death Dis. 2015 Feb 05;6:e1629
pubmed: 25654762
Iran J Microbiol. 2023 Jun;15(3):475-481
pubmed: 37448673
Sci Signal. 2016 Sep 13;9(445):ra90
pubmed: 27625304
Biomed Pharmacother. 2017 Jan;85:334-347
pubmed: 27887847
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Leuk Res. 2018 Jan;64:17-23
pubmed: 29149649
Cancers (Basel). 2022 May 12;14(10):
pubmed: 35625999
Front Immunol. 2022 Apr 29;13:875211
pubmed: 35572593
Biosci Rep. 2022 Mar 31;42(3):
pubmed: 35169839
Development. 2015 Apr 15;142(8):1516-27
pubmed: 25813538
Lancet Oncol. 2014 Oct;15(11):e517-26
pubmed: 25281470
AIDS Res Hum Retroviruses. 2005 Apr;21(4):273-84
pubmed: 15943569
J Immunol. 2012 Jan 1;188(1):182-9
pubmed: 22124122
PLoS Comput Biol. 2011 Jan 20;7(1):e1001057
pubmed: 21283776
Oncogene. 2013 Sep 5;32(36):4222-30
pubmed: 23045287
PLoS One. 2021 Feb 25;16(2):e0247713
pubmed: 33630973
Viruses. 2022 Mar 12;14(3):
pubmed: 35336993
J Clin Invest. 2021 Dec 15;131(24):
pubmed: 34907908
Invest New Drugs. 2021 Feb;39(1):122-130
pubmed: 32914311
J Hematol Oncol. 2018 Sep 19;11(1):119
pubmed: 30231940
Cell Death Differ. 2019 Dec;26(12):2551-2567
pubmed: 30894677
Bioinformatics. 2010 Dec 15;26(24):3135-7
pubmed: 21123224
Int J Mol Sci. 2022 May 14;23(10):
pubmed: 35628297
Front Microbiol. 2017 Aug 02;8:1425
pubmed: 28824561
Biochem Biophys Res Commun. 2003 Jan 3;300(1):128-34
pubmed: 12480531
IUBMB Life. 2009 Jun;61(6):685-92
pubmed: 19472191
Blood. 2013 Jun 20;121(25):5045-54
pubmed: 23660959
Cancer Treat Rev. 2020 Aug;88:102026
pubmed: 32592909
Nat Rev Mol Cell Biol. 2013 Dec;14(12):752
pubmed: 24201108
J Virol. 2010 Sep;84(17):8732-42
pubmed: 20573814
Int J Hematol. 2018 Mar;107(3):337-344
pubmed: 29043551
Virus Res. 2022 Oct 02;319:198875
pubmed: 35868352
J Clin Virol. 2011 Nov;52(3):172-6
pubmed: 21840754
J Immunol. 2014 May 1;192(9):4386-97
pubmed: 24706725
Radiother Oncol. 2018 Mar;126(3):450-464
pubmed: 29054375
Cancer Metastasis Rev. 2018 Dec;37(4):767-778
pubmed: 30171384
Bioinformatics. 2014 Feb 01;30(3):360-8
pubmed: 24292935
Cell. 2017 Jun 1;169(6):985-999
pubmed: 28575679